Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,601–1,700 of 1,871
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Mishra, A., mishra, P., Bajaj, S., Kalra, P., Mishra, V., Bhat, S., Patni, B., Abichandani, V. K., Farishta, F., Aggarwal, V., et al. (2026) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2026.100865
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70715 · Cited by 7
Promoviendo giros en el manejo de la enfermedad renal del paciente con obesidad
Lecube, A., Zamora, J. I., Azriel, S., Barreiro, E., Blay, G., Carretero‐Gómez, J., Ciudin, A., Fernández-García, J. M., Flores, L., de Hollanda, A., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501358
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
“Beyond glycemic control, prospective cardiovascular and renal outcome trials, such as SUSTAIN-6, PIONEER, and the FLOW trial, have demonstrated cardiovascular, metabolic, and renal benefits [34–36].”
Li, J. Z., González-Villalobos, R. A., Rutkoski, T. J., Farrington, K. P., Chipashvili, V., Zheng, G., Chen, T., Yekkala, K., Locatelli, M., Zoja, C., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001176
Rabbani, S. A., Alkoud, H. A., El‐Tanani, M., Mahmoud, E. A. O., Mohamed, E. E. H. A., Zabadi, G. K., Muzaffar, H., & Qasem, A. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145577
“Thus, the short-term eGFR rise observed here should not be interpreted as structural improvement but rather as a measurement phenomenon requiring longer follow-up and comparator-controlled designs to distinguish from true disease-modifying change [16,19].”
InfluentialDiabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes
Hansrivijit, P., Patorno, E., Tesfaye, H., Wexler, D. J., Roh, M., & Paik, J. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101518
Stracke, S., Kiel, S., Negnal, M., Mathias, L., Mathias, E., Uebel, T., Baum, E., Fleig, S. V., Kuhlmann, M. K., Galle, J., et al. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00860-4
Potential Benefits of Remission of High Childhood BMI Keep Increasing
Bjerregaard, L. G. (2025) · Diabetes Care · doi:10.2337/dci25-0084 · Cited by 1
GLP-1 medications and health equity: when insurance access determines who benefits
Arif, S., Chaudhary, A., Ullah, S., et al. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag128
Ananeva, A. S., Romashova, A. P., Bryndina, A. E., et al. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202528081110
Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?
Tantisattamo, E., & Ku, E. (2026) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2026.02.003
Wynter, L. A., Smyth, B. J., Saunders, J., Moroney, C., Gorringe, L., Turner, K., Venugopal, S., Tienstra, L., Monteverde, R., Kang, A., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094554
“16 In people with DKD, combination therapy with these agents likely provides additive benefits in reducing cardiovascular events and CKD progression.”
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
“…disease progression; semaglutide recently received an FDA label to reduce risk of kidney function decline, end-stage kidney disease, and renal death in at-risk individuals with T2D based on the results of the FLOW trial studying 1 mg semaglutide qw over a mean follow-up period of 3.4 years (205).”
InfluentialFarmakovijilansın Önemi: GLP-1 Reseptör Agonistlerinin Etkinlik ve Güvenliliği
Kayan, G. T., & Karataş, Y. (2026) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1976223
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
Gerdes, C., & Wolf, G. (2025) · Nephrologie aktuell · doi:10.1055/a-2536-2689
Başer, O., & Lu, Y. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2518329
“…No. 03819153), evaluated the efficacy and safety of semaglutide, a GLP-1 receptor agonist, and found it 24% protective in preventing kidney failure, substantial kidney function loss, and death from kidney-related or cardiovascular causes in patients with type 2 diabetes and CKD [6].”
Research Progress on the Association between Chronic Diabetes Complications and Adverse Outcomes
Zhu, X.-T. (2026) · Hans Journal of Food and Nutrition Science · doi:10.12677/hjfns.2026.152020
Levi, J., Cross, S., Ramesh, N., Venter, F., & Hill, A. M. (2026) · Obesity · doi:10.1002/oby.70241 · Cited by 8
Hat die inkretinbasierte Hypertoniebehandlung eine Zukunft?
Zidek, W. (2026) · CardioVasc · doi:10.1007/s15027-025-3944-5
“ekanntlich haben die GLP-1-Re-zeptoragonisten ausgehend von der ursprünglichen Indikation mellitus auch im Bereich der Nephro-und Kardioprotektion einen wichtigen Stellenwert erhalten [1, 2, 3, 4].”
Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults
Toma, L., Buckley, K. D., & Early, N. K. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.78
Place des nouvelles classes thérapeutiques dans la stratégie de prise en charge du diabète de type 2
Gourdy, P. (2024) · Pratiques en nutrition · doi:10.1016/j.pranut.2024.08.003
Khogalee, M., Mohamed, S., Otim, M. E., Basher, M., Mumtaz, M., Thaslim, S., & Houni, A. E. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.08.004
Ali, F., & Farzand, M. (2025) · Kidney News · doi:10.62716/kn.000092024
Nasri, H., Chitsazi, M. R., Abbasi, F., Ashouri, A. H., Rouzbahani, H., Mirzaei, S. A., Golafshan, F., Noursina, A., & Safari, F. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00884-9
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Ramadurgum, P., Shah, J., Shah, E., & PALMER, B. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917800
“In the FLOW trial, once-weekly subcutaneous semaglutide reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease (CKD), and slowed the annual loss of estimated glomerular filtration rate (eGFR) by 1.16 mL/min/1.73 m 2 (Perkovic et al., 2024).”
InfluentialLindhardt, R. B., Rasmussen, S. B., Machado, M., et al. (2026) · BMJ Digital Health & AI · doi:10.1136/bmjdhai-2025-000172
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Ishioka, H., Iwamura, Y., Konta, Y., Sato, K., Kato, K., Tanaka, T., Nakai, T., & Suzuki, N. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124599
Tian, Z., Sternberg, M., Willerding, J. M., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. (2026) · medRxiv · doi:10.64898/2026.01.28.26345070
Jafar, T. H., Zhu, A., & Ogungbe, O. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001173
Amamoo, J. J., Wang, Y., Liu, H., Sundar, M., Song, Y., Xie, L., MEHANNA, S. J., Noone, J. M., Swift, C., & Weir, M. R. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03744-8
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease
Tuttle, K. R., Cherney, D. Z. I., Pecoits-Filho, R., Pirro, M., Yau, K., & Sahay, M. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106712 · Cited by 1
Self-citationSpennati, G., Vo, N., Regier, M. C., Ward, H. H., Das, V., Karihaloo, A., & Freedman, B. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103081 · Cited by 5
Finerenone and Cardiorenal Outcomes: A Narrative Review
Fernandes, W., Tasneem, S., Latif, F., Soussi, Y. E., Saji, A., Jani, A., Fuqaha, F., MOHAMMED, R. U. H., Leiva, D. M., Iliasov, M., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001377
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
“39 101 These therapies also confer significant cardiovascular and renal protection in high-risk populations, 102–106 establishing pharmacotherapy as a cornerstone of modern cardiometabolic disease management.”
Tuttle, K. R. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00863-x
Self-citationPeng, Z., Liang, X., Su, L., You, Z., Zhu, L., Yang, Y., Wang, Y., Liu, D., & Liang, M. (2026) · American Journal of Nephrology · doi:10.1159/000552163
Indennidate, C., Perencin, B., Maso, V. D., Buda, I., Candido, R., Sinagra, G., & Merlo, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02340-6 · Cited by 1
“The FLOW trial demonstrated a significant reduction in the risk of kid - ney failure and major cardiovascular events in patients with type 2 diabetes and chronic kidney disease [64].”
Kasaie, P., Zhao, Y., Humes, E., Gerace, L., Reid, K., Lesko, C. R., Kurgansky, K. E., Koethe, J. R., Rebeiro, P. F., Bourgi, K., et al. (2026) · Annals of Epidemiology · doi:10.1016/j.annepidem.2026.110292
Diabesidad: concepto e implicancias
Lahsen, R. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.08.010
“En estudios más recientes, en pacientes con enfermedad cardiovascular y renal establecida, semaglutida de administración subcutánea demostró una reducción de un 24% en el resultado compuesto de progresión de la enfermedad renal crónica, muer-te cardiovascular y muerte renal 43 .”
The kidney as sensitive marker of disease severity in cardiogenic shock after myocardial infarction
Damman, K., Legtenberg, S., & ter Maaten, J. M. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf095
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · Research Square · doi:10.21203/rs.3.rs-9407045/v1
Cabello, M. I. E., Álvarez, P. A., Moraga, M. J. C., Cuenca, A. M. C., Cols-Sagarra, C., Hernández, Y. D., Ramos, P. G., Obaya, J. C., & Gil, F. A. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102813
Chang, C.-H., & Tsai, S. (2026) · Science Progress · doi:10.1177/00368504261468477
“6 Furthermore, novel agents such as finerenone 7,8 and semaglutide 9 have demonstrated renal benefits in patients with diabetic kidney disease.”
Stopping Trials Early for Benefit
Kaul, S., & Butler, J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.026
Zhou, H., Li, X., Zheng, Z., Tang, W., Wu, X., & Fan, C. (2026) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203261427139
Semaglutide and the Heart: Focus on Their Love–Hate Relationship
Khan, E., Fernandes, J., Gohel, V., Jain, R., Jayne, W., Peck, C., Shah, T. S., Shah, R. S., LaBarge, J., Ray, S. D., et al. (2026) · Hearts · doi:10.3390/hearts7030022
GLP-1 Receptor Agonists and Muscle Loss in Chronic Kidney Disease
Sawaira, F., Mahmood, H. A., Ameer, M. H., Abbas, A., Ullah, G., Hassan, I., Ehsan, N., & Ahmed, N. A. T. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002218
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.51.90.102
A Perspective on the Role of Nephrologists in the Cardiovascular-Kidney-Metabolic Syndrome
Sridhar, V. S., & Levin, A. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.06.018
Marx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Aktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00258-6
Janota, O., Kwiendacz, H., Olejarz, A., Włosowicz, A., Pabis, P., Gumprecht, J., Alam, U., Lip, G. Y. H., & Nabrdalik, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2392017
“F L O W [ 42 ] 202 4 Finerenone, a non-steroidal, mineralocorticoid receptor (MR) antagonist, antagonize the effects of aldosterone, including absorption of the sodium in the distal nephron and generalized vasoconstriction (rev. in [16]).”
InfluentialUnderstanding the Impact of Systemic Medications on Diabetic Retinal Disease
Silva, P. S. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.03.006
Gembillo, G., Casuscelli, C., Spada, A. L., Pietro, Y. D., Cipressa, G., Santoro, D., & Re, C. L. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2706076
Corrêa, L. M. D. A., Brandão, L., Silva, Y. R. D., Ferreira, G. D., Mazur, G. R., & Arruda, S. L. P. (2026) · Translational research · doi:10.1016/j.trsl.2026.07.001
Wohlfeld, C., Blas, A., Woodruff, J., Frick, M., Maciejewska, N., Patel, A., Grillo, C. A., Reagan, L. P., & Fadel, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742612
Okhovat, V., Lybeshari, K., Cubeddu, L. X., & Hale, G. M. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00829-1
Peng, J., Yin, B., Xiang, J., Lin, L., Huang, H., & Wu, F. (2026) · European journal of medical research · doi:10.1186/s40001-026-04614-3
“Simultaneously, the mortality rate among diabetic patients has been increasing year by year, with diabetes and its complications—such as heart disease and kidney disease—significantly elevating the risk of kidney failure, cardiovascular events, and premature death [8, 9].”
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
“We did see increased risks of gastrointestinal symptoms (i.e., positive control outcome), consistent with findings from clinical trials 4-7, 10 Three previous studies have also evaluated the effectiveness of GLP-1s on mortality in patients receiving hemodialysis, and GLP-1 use was associated with…”
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Pigsborg, K., Kienle, S. M., Wretlind, A., Curovic, V. R., Blond, M. B., Heerspink, H. J. L., Hansen, T. W., Persson, F., Sulek, K., Legido‐Quigley, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71130
“Furthermore, GLP-1 RA has also been shown to reduce the progression of kidney disease, cardiovascular outcomes and mortality in individuals with T2D and chronic kidney disease [36].”
Self-citationFrom adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
“Improved end-organ hard outcomes using these therapies in individuals with obesity and established ASCVD[17], HF with preserved ejection fraction[18,43], MASH or fibrosis[44,45], and CKD,[46] demonstrate the modifiability of multiple health outcomes resulting from obesity.”
Adherence to Antihypertensive Medications in Chronic Kidney Disease
Damianaki, A., & Burnier, M. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_13
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Zhang, J. K., Gao, G., He, M., & Sun, T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178921
Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future
Everett, B. M., Pagidipati, N. J., & Wang, C. C. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00011-2
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
Implicit Rationing of Incretin Therapy in Diabetic Kidney Disease: A Call for Deliberate Allocation
de Silva, D., & Peiris, A. (2026) · Cureus · doi:10.7759/cureus.115170
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Kidney dysfunction and pulmonary vascular disease in heart failure with preserved ejection fraction
Amdahl, M. B., Naser, J. A., Tada, A., Doi, S., Harada, T., Ibe, T., Testani, J. M., Melenovský, V., Reddy, Y. N. V., & Borlaug, B. A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag140 · Cited by 2
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
“The FLOW trial, which included patients with T2D and CKD, found that semaglutide improved renal outcomes but Black individuals represented only 4% of the trial population [27].”
Bewährtes und Neues in der Therapie der Herzinsuffizienz
Schwenger, V. (2025) · Die Nephrologie · doi:10.1007/s11560-024-00821-3
Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors
Ni, H., Piggott, S., Festa, M. C., Faruque, L. I., & Cherney, D. Z. I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2723583
“The trial was terminated early for efficacy and demonstrated a 24% reduction in the primary outcome of major kidney disease events [83].”
Authors reply: Obesity treatment in adolescents and adults in the era of personalized medicine
Sundbom, M., Järvholm, K., Sjögren, L., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20062
Metabolism in PTEN hamartoma tumour syndrome
Ambery, P., Bågenholm, R., Pepper, T., Barton, C. M., Whitehead, M. A., Rodriguez, L. H., & Greasley, P. J. (2026) · Metabologia · doi:10.1007/s44357-026-00008-4
崔, 博. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.54253
Branch, K. R., Lam, C. S. P., Islam, S., Prato, S. D., Lópes, R. D., Pratley, R. E., Rosenstock, J., Sattar, N. A., & Gerstein, H. C. (2025) · Diabetes Care · doi:10.2337/dc24-2629
Self-citationKim, H. S., Kim, M., Kim, H. S., Cho, Y. K., Jung, C. H., & Lee, W. J. (2025) · Clinical Endocrinology · doi:10.1111/cen.70078
“The landmark FLOW trial demonstrated that semaglutide significantly reduced chronic kidney disease (CKD) morbidity and mortality in patients with T2DM, thereby extending the therapeutic relevance of GLP‐1RAs beyond glycemic and cardiovascular outcomes [11].”
Hass, D., Madsen, A. N., da Silva‐Buttkus, P., Kjølbye, A. L., Støy, S. H., Nøhr-Meldgaard, J., Sandahl, T. D., de Angelis, M. H., Jørgensen, R., Rohm, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.041
Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.116477
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
“Die nephroprotektiven Wirkungen der GLP-1-Rezeptor-agonisten rena-len Endpunkt hatte [8].”
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7 · Cited by 1
“It has also reduced major adverse cardiovascular events by 20% in the SELECT trial and conferred significant renal protec - tion in the FLOW study [ 32, 42 ].”
Adinolfi, G., Milia, V., Dinkov, B., & Stavreva, G. (2026) · Endocrines · doi:10.3390/endocrines7010009 · Cited by 1
“Regarding study population, FLOW was specifically designed to enroll patients with established CKD, defined by an eGFR of 25–75 mL/min/1.73 m 2 and significant albuminuria, representing a population at substantially elevated cardio-renal risk [16].”
InfluentialIn remembrance: the life and legacy of George L. Bakris (1952–2024)
Sarafidis, P. A., Tsioufis, K., Burnier, M., Williams, B., Mancia, G., Weber, T., Stergiou, G. S., & on behalf of the European Society of Hypertension and the International Society of Hypertension (2024) · Blood Pressure · doi:10.1080/08037051.2024.2390774
“…all the four current pillars of kidney disease treatment, i.e. renin-angiotensin-sys-tem blockers with the AASK trial [1], sodium-glucose-transporter 2 inhibitors with CREDENCE [2], finerenone with FIDELIO and FIGARO [3,4] and, recently, glucagon-like peptide-1 receptor agonists with FLOW-CKD [5].”
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“…1 mg/week administered to patients with type 2 diabetes and CKD resulted in a 24% decreased risk of composite outcome including initiation of long-term dialysis or transplantation, reduction in eGFR 15, sustained reduction in eGFR, or death from kidney-related or cardiovascular causes [50].”
AlTaweel, M., Almekhloof, S., Alkhayyal, A. K., AlRashada, J. Y., Alohaymid, M., Alshahrani, A., Alarfaj, A. W., Alqarni, T., Almoaibed, G., & Altharman, N. M. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2713476
“The FLOW trial showed that semaglutide reduced major kidney outcomes in patients with type 2 diabetes and chronic kidney disease [18], and the SELECT trial showed cardiovascular benefit of semaglutide in patients with established cardiovascular disease and overweight or obesity, independent of…”
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“However, the ongoing FLOW trial, a randomized controlled trial of semaglutide in patients with type 2 diabetes and chronic kidney disease (eGFR 25–75 mL/min/1.73 m 2 and urine albumin-to-creatinine ratio (UACR) ≥ 200 mg/g), is the first to evaluate renal outcomes as a primary endpoint [32].”
InfluentialInterpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy
Groothof, D., de Vries, M., Erler, N. S., et al. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100200
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 2
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.